For the quarter ending 2025-09-30, TRDA had $20,804K increase in cash & cash equivalents over the period. -$28,142K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -44,134 | -60,452 |
| Depreciation expense | 1,230 | 1,980 |
| Stockbased compensation expense | 5,116 | 10,135 |
| Amortization/(accretion) of marketable securities | 739 | 2,299 |
| Collaboration receivable | 16 | -2,500 |
| Prepaid expenses and other current assets | -3,731 | -2,407 |
| Right-of-use assets, operating leases | -3,559 | -5,439 |
| Other non-current assets | -36 | -85 |
| Accounts payable | 1,309 | -2,231 |
| Accrued expenses and other current liabilities | 3,737 | -1,145 |
| Income tax payable | 620 | -667 |
| Operating lease liabilities | -2,343 | -4,464 |
| Deferred revenue | -419 | -19,284 |
| Net cash used in operating activities | -28,313 | -67,996 |
| Purchases of property and equipment | -171 | 1,419 |
| Purchases of marketable securities | 26,566 | 96,574 |
| Maturities of marketable securities | 75,504 | 136,573 |
| Net cash provided by (used in) investing activities | 49,109 | 38,580 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid | 0 | 0 |
| Proceeds from exercise of stock options | 8 | 370 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 0 | 317 |
| Net cash provided by financing activities | 8 | 687 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 20,804 | -28,729 |
| Cash and cash equivalents at beginning of period | 105,161 | - |
| Cash and cash equivalents at end of period | 97,236 | - |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)